文献速递青光眼

Rho激酶抑制剂作为青光眼和高眼压症的新型治疗

Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension.
PubMed 文献 · Ophthalmology · 2018-07-12

本文综述Rho激酶抑制剂从基础研究到临床应用的转化历程,重点介绍其降眼压机制及已获批药物利舒地尔(日本)和奈他地尔(美国)。这类药物可单用或联合降眼压,并可能具有神经保护、改善眼血流和抗纤维化作用,但局部不良反应常见。

要点

  • Rho激酶抑制剂是自1996年拉坦前列素获批以来首个新类降眼压药。
  • 利舒地尔在日本、奈他地尔在美国已获批用于临床。
  • 常见局部不良反应包括结膜充血、结膜下出血和角膜垂直纹。

核心结论

  • Rho激酶抑制剂是青光眼和高眼压症降眼压治疗的新一类药物,代表转化研究的成功。

研究设计与样本

  • 本文为综述,描述Rho激酶抑制剂降眼压治疗的基础科学并总结已报道的临床研究结果。

主要发现

  • Rho激酶抑制剂单用或与其他已知降眼压药物联用均有效。
  • 可能具有神经保护活性、对眼血流的有利影响以及抗纤维化效应。
  • 局部不良反应常见,包括结膜充血、结膜下出血和角膜垂直纹。

关键数值与推荐

  • 已获批临床使用的药物为日本利舒地尔和美国奈他地尔。

临床怎么用

  • Rho激酶抑制剂可单独或联合用于青光眼和高眼压症患者的降眼压治疗。
  • 其抗纤维化特性可能对常规青光眼手术有用。

局限性

  • 局部不良反应常见。
  • 靶向流出通路细胞和视网膜的Rho激酶抑制剂尚在开发中,可能带来更大临床影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In an elegant example of bench-to-bedside research, a hypothesis that cells in the outflow pathway actively regulate conventional outflow resistance was proposed in the 1990s and systematically pursued, exposing novel cellular and molecular mechanisms of intraocular pressure (IOP) regulation. The critical discovery that pharmacologic manipulation of the cytoskeleton of outflow pathway cells decreased outflow resistance placed a spotlight on the Rho kinase pathway that was known to regulate the cytoskeleton. Ultimately, a search for Rho kinase inhibitors led to the discovery of several molecules of therapeutic interest, leaving us today with 2 new ocular hypotensive agents approved for clinical use: ripasudil in Japan and netarsudil in the United States. These represent members of the first new class of clinically useful ocular hypotensive agents since the US Food and Drug Administration approval of latanoprost in 1996. The development of Rho kinase inhibitors as a class of medications to lower IOP in patients with glaucoma and ocular hypertension represents a triumph in translational research. Rho kinase inhibitors are effective alone or when combined with other known ocular hypotensive medications. They also offer the possibility of neuroprotective activity, a favorable impact on ocular blood flow, and even an antifibrotic effect that may prove useful in conventional glaucoma surgery. Local adverse effects, however, including conjunctival hyperemia, subconjunctival hemorrhages, and cornea verticillata, are common. Development of Rho kinase inhibitors targeted to the cells of the outflow pathway and the retina may allow these agents to have even greater clinical impact. The objectives of this review are to describe the basic science underlying the development of Rho kinase inhibitors as a therapy to lower IOP and to summarize the results of the clinical studies reported to date. The neuroprotective and vasoactive properties of Rho kinase inhibitors, as well as the antifibrotic properties, of these agents are reviewed in the context of their possible role in the medical and surgical treatment of glaucoma.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Tanna AP, Johnson M. Rho Kinase Inhibitors as a Novel Treatment for Glaucoma and Ocular Hypertension. Ophthalmology. 2018. PMID: 30007591. doi:10.1016/j.ophtha.2018.04.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。